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Abstract
Arginylation is an emerging posttranslational modification mediated by arginyltransferase (ATE1) 
that is essential for mammalian embryogenesis and regulation of the cytoskeleton. Here, we 
discovered that Ate1 knockout embryonic fibroblasts exhibit tumorigenic properties, including 
abnormally rapid contact-independent growth, reduced ability to form cell-cell contacts, and 
chromosomal aberrations. Ate1 knockout fibroblasts can form large colonies in Matrigel and 
exhibit invasive behavior, unlike wild type fibroblasts. Furthermore, Ate1 knockout cells form 
tumors in subcutaneous xenograft assays in immunocompromised mice. Abnormal growth in these 
cells can be partially rescued by reintroduction of stably expressed specific Ate1 isoforms, which 
also reduce the ability of these cells to form tumors. Tumor array studies and bioinformatics 
analysis show that Ate1 is down-regulated in several types of human cancer samples at the protein 
level, and that its transcription level inversely correlates with metastatic progression and patient 
survival. We conclude that Ate1 knockout results in carcinogenic transformation of cultured 
fibroblasts, suggesting that in addition to its previously known activities Ate1 gene is essential for 
tumor suppression and also likely participates in suppression of metastatic growth.
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Introduction
Protein arginylation is an emerging posttranslational modification mediated by 
arginyltransferase ATE1 (1). Arginylation was originally discovered in 1963 (2), and was 
shown through recent studies to play a global role in many biological processes, including 
cardiovascular development, angiogenesis (3), cell migration (4), and tissue morphogenesis 
(5). Over 100 arginylated proteins have been identified in vivo (5–8), and this list is growing 
by the day.
Despite growing evidence of the importance of arginylation, its exact biological functions in 
normal physiology and disease remain poorly understood. Ate1 knockout mouse embryonic 
fibroblasts exhibit pronounced defects in migration and adhesion reminiscent of cancer cells 
(4, 9). However, a disease connection between arginylation and cancer has never been 
explored (10).
Here we addressed the possibility that Ate1 knockout confers cancerous phenotypes at the 
cellular level. We found that Ate1 knockout in cultured cells leads to contact-and substrate-
independent cell growth, formation of subcutaneous tumors in xenograft studies, and that 
reduction in Ate1 levels correlates with cancer and is particularly associated with metastatic 
potential. Our study is the first direct demonstration of Ate1 role in cancer, identifying Ate1 
as a potential novel tumor suppressor and a biomarker for metastatic cancers.
Results
Ate1 knockout cells exhibit density-and serum-independent growth and chromosomal 
aberrations
Our previously published data show that immortalized Ate1 knockout (KO) mouse 
embryonic fibroblasts (MEF) exhibit defects in cell spreading (4) and cell-cell adhesion (9). 
Working with these cells, we observed that they generally grew to higher densities at 
confluency than the similarly treated wild type cells. To test if Ate1 KO cells grow 
differently than wild type, we quantified their multiplication rates in comparison to similarly 
derived and immortalized wild type MEF. In these assays, wild type cells typically reached 
confluency at 3–4 days post-inoculation and continued to survive in culture plates as a 
monolayer without undergoing further multiplication (Fig. 1A). In contrast, Ate1 KO MEFs 
continued to grow and multiply even after reaching confluency, eventually growing to the 
densities over 10-fold higher than wild type (Fig. 1A). Notably, such contact-independent 
growth is characteristic for many cancer cells and ultimately underlies their ability to form 
tumors and metastases.
To further test whether Ate1 KO cells exhibit behavior similar to cancer cells in culture, we 
studied the ability of these cells to grow and multiply under low serum conditions, which 
inhibit the growth of normal, but not highly malignant cells. To do this, we performed 
growth curves similar to those shown in Fig. 1A, using immortalized WT and Ate1 KO cells 
grown in 0.5% serum. While both cell types grew slower during serum deprivation, Ate1 KO 
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cells were able to reach much higher densities compared to WT (Fig. 1B and S1), suggesting 
that these cells can actively divide even in very low serum.
Experiments showed that the contact-independent growth was observed only in 
immortalized Ate1 KO MEFs, but not in primary cultures freshly derived from Ate1 KO 
mouse embryos (Fig. 1C), suggesting that this quality is acquired by these cells with 
additional changes that occur during immortalization. Notably, however, even in the primary 
fibroblasts freshly derived from E12.5 mouse embryos, the karyotypes were highly abnormal 
(Fig. 1D), suggesting that these cells have already accumulated genetic defects that may 
result in further abnormalities after immortalization.
The abnormal growth of Ate1 KO cells is associated with defects in contact inhibition
The abnormally high multiplication rates seen in Ate1-KO cells could be explained by either 
an overall reduction in cell doubling time that drives them to divide at a faster rate, or by 
compromising contact inhibition – a process commonly seen in non-cancerous cells, which 
inhibits cell migration and proliferation upon sensing the proximity to their neighbors. To 
directly test these two possibilities, we cultured the Ate1-KO and WT cells at varying 
densities and examined their multiplication rates under these conditions. In scarce cultures, 
where cells largely remain isolated from each other, both Ate1-KO and WT cells multiplied 
at nearly equal rates (Fig. 2A), suggesting that in the active growth phase without proximity 
to their neighbors these cells have largely similar doubling time. However, when plated in 
dense cultures, Ate1-KO cells multiplied much faster than WT cells (Fig 2B). This 
difference of growth in dense cultures can be explained either by difference in apoptosis 
rates, or by difference in contact-inhibit. To test these possibilities, we first used Terminal 
deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) assay to measure the rate 
of apoptosis in confluent WT and Ate1 KO cells. We found that both types of cells have 
negligible levels of apoptosis in such conditions, which cannot account for their difference in 
cell proliferation (Fig. S2A). We next tested whether Ate1 KO cells exhibit characteristic 
morphological changes that accompany defects in contact inhibition, including reduced cell-
cell contacts and foci formation in culture. Indeed, while the WT MEF formed normal cell 
monolayers in dense culture, the Ate1-KO cells tended to cluster and form foci, with 
multiple layers of cells piling on top of each other (Fig. 2C). Furthermore, consistent with 
our prior observations (Zhang et al 2012), Ate1-KO cells showed a greatly reduced ability to 
form cadherin-containing cell-cell adhesions, further confirming that these cells have 
reduced ability to contact each other (Fig. 2D).
In normal cells, contact inhibition is accompanied by decreased cell cycle activity in dense 
cultures. Impairments in contact inhibition are expected to result in higher cell cycle activity 
at confluency. To test whether confluent Ate1 KO cells have higher entry rates into S-phase 
compared to WT, we double-labeled the cells with a thymidine analogue, 5-ethynyl-2′-
deoxyuridine (EdU), which is incorporated into DNA during the S phase of cell cycle. In 
addition, Hoechst 33342 or 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI) was 
also used to uniformly label DNA. We then used imaging and cell sorting to compare the 
cell cycle distribution and the amount of cells with actively replicating DNA in WT and 
Ate1 KO (Fig. 3 and Fig. S2B,C). In both scarce and confluent cultures, the percentages of 
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EdU-labeled cells in S-phase as well as the overall cell distribution over different cell cycle 
stages, were very similar between Ate1-KO cells and WT cells. However, in confluent 
cultures, Ate1-KO cells had much higher percentage (nearly 2-fold) of actively replicating 
cells compared to WT. These data suggest that Ate1-KO cells continue to be active in the 
cell cycle in dense cultures and do not undergo contact inhibition like WT MEF.
Ate1 KO MEF grow large colonies in Matrigel and form tumors in xenograft studies
The abnormal growth and lack of contact inhibition seen in Ate1 KO cells are reminiscent of 
cancer cells, which often show contact-independent and serum-independent growth and foci 
formation in culture. Other prominent characteristics of cancer cells are their ability to form 
large invasive colonies in soft 3D matrices and form subcutaneous tumors when injected into 
mice.
To test these properties, we first examined the behavior of Ate1 KO cells grown suspended 
in Matrigel, which provides a simulated microenvironment of extracellular matrix through 
which tumorigenic and invasive cells may grow. Over the course of 4 weeks, WT cells 
remained embedded in the matrix as small cell aggregates without exhibiting significant 
growth. At the same time Ate1 KO cells continued to grow at very high rates, forming large 
colonies that, after week 1, began active invasion into the matrix and eventually occupied 
most of the matrix as large cell masses (Fig. 4).
We next injected Ate1 KO cells subcutaneously into immunocompromised (NCr −/−) mice 
to test if these cells are able to form tumors in this assay (Fig. 5). The same mice were 
simultaneously injected with wild type cells on the left flank and with the same amount of 
Ate1 KO cells on the right flank at a symmetric site (the injection sites are marked by 
asterisks in Fig. 5, with black asterisks for WT cells and red asterisks for Ate1 KO cells, 
respectively). Remarkably, all the injected mice developed prominent tumors on the right 
flank over the course of 6 weeks, while showing no visible or palpable tumor growth on the 
left (Fig. 5).
Thus, Ate1 KO cells show potent tumorigenic properties in their ability to grow and invade 
in soft matrices and form subcutaneous tumors in mice.
Ate1 KO cells’ abnormal growth and tumorigenicity can be partially rescued by specific 
Ate1 isoforms
Our grows assays (Fig. 1) indicate that only the immortalized, but not the primary Ate1 KO 
cells have abnormal growth rates, suggesting that Ate1 knockout may trigger tumorigenic 
changes in these cells down the road but may by itself be not sufficient to induce 
tumorigenicity. At the same time, it is possible that some, or many of the abnormalities in 
the immortalized cultures are driven directly by the ongoing deficiency of Ate1-mediated 
arginylation. To test this possibility, we performed rescue experiments, by stably transfecting 
Ate1 KO MEFs with individual GFP-fused Ate1 isoforms 1–4 (11). The level of 
exogenously expressed Ate1 in KO cells was determined to be comparable to that of 
endogenous Ate1 in WT cells (Fig. S3). We then accessed the growth rates of these cells in 
culture, in comparison to Ate1 KO MEFs transfected with GFP alone. Remarkably, while all 
of the transfected cultures still grew at relatively high rates (Fig. 6A), transfection with Ate1 
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isoforms 1 and 3 partially reduced the growth rates of these cells (Fig. 6A, left), although 
isoforms 2 and 4 showed no visible effect on cell growth compared to GFP alone (Fig. 6A, 
right). These data suggest that the lack of Ate1 (at least certain isoforms) is the direct reason 
for at least some of the abnormal growth effects of the Ate1 KO cells seen in culture.
To test whether the lack of Ate1 is also directly contributing to tumor growth seen in 
immunocompromised mice, we performed tumor xenograft studies in NCr−/− mice, 
injecting each mouse with the Ate1-transfected Ate1-KO cells on one side and the GFP-
transfected Ate1-KO cells on the other side. In these assays, Ate1-1 and Ate1-3-transfected 
cells grew much slower than control and formed significantly smaller tumors over the course 
of several weeks, suggesting that the genetic deletion of Ate1 was at least one of the direct 
causes for the tumor growth (Fig. 6B). At the same time, Ate1-2 transfected cells formed 
tumors at the rates similar to the control (Fig. S4).
Ate1 level is reduced in human cancer and inversely correlates with metastatic 
progression
Our data so far suggest that Ate1 knockout confers tumorigenic properties to cultured mouse 
fibroblasts. An exciting possibility that can be extrapolated from these results is that Ate1 
possesses tumor suppressor characteristics and that its levels may inversely correlate with 
carcinogenic properties of multiple cell types involved in cancer. To test this possibility, we 
tested tissue arrays of human colon and kidney carcinomas using immunohistochemistry 
with anti-Ate1 antibodies. Remarkably, in both arrays, the average level of Ate1 staining was 
significantly lower in the tumor samples compared to the matched samples of normal tissues 
from the same patients (Fig. 7A). Consistent to the results seen in our immunostaining 
assays, database searches of published data on patient tumor samples showed that mRNA 
level of Ate1 is significantly lower in malignant types of kidney cancers (chromophobe renal 
cell cancer, collecting duct carcinoma, conventional renal cell cancer, papillary renal cell 
cancer, and Wilm’s tumor), compared to the non-diseased kidney tissues or the relatively 
benign kidney tumors (renal lipoma and renal oncocytoma) (Fig. 7B). Moreover, low Ate1 
mRNA levels were also associated with poor survival prognosis in human colon cancer 
patients (Fig. 7C).
Ate1-KO is known to cause defects in cell migration (4), adhesion (9), and E-cadherin 
expression (12), which are commonly indicative of enhanced cancer invasion and EMT. In 
addition, Ate1 KO cells also exhibit invasive growth in Matrigel (Fig. 4). Therefore, in 
addition to the tumorigenic properties, Ate1-KO is also likely to contribute to metastasis/
invasion. Indeed, in at least one study of prostate cancer progression, Ate1 mRNA levels 
were lowered in primary non-metastatic tumor compared to non-diseased tissues, and in two 
different studies Ate1 mRNA levels were further reduced in metastatic prostate cancer 
tissues compared to the primary tumors (Fig. 7D). These data suggest that the down-
regulation of Ate1 is not only correlated with cancer, but also potentially associates with the 
progression of cancer toward metastasis.
Rai et al. Page 5
Oncogene. Author manuscript; available in PMC 2016 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
This study is the first demonstration of a direct effect of Ate1 knockout on cell 
tumorigenicity, correlated with Ate1 expression level in clinical samples. It has been 
previously shown that Ate1 is a global biological regulator that plays a major role in 
embryogenesis and drives cell migration, adhesion, and the assembly and functions of the 
actin cytoskeleton. Our current data represents a significant expansion in the scope of the 
emerging protein arginylation studies and establishes a novel role of Ate1 in cancer. Our 
data show that Ate1 KO cells have prominent defects in contact inhibition, the properties 
that likely enable their uncontrolled growth in dense cultures and in Matrigel, as well as 
subcutaneous tumor formation in xenograft studies. In agreement with these observations, 
Ate1 is down-regulated in human cancers and its expression is further reduced in metastatic 
tissues.
Our data show that immortalized Ate1 KO MEF can form subcutaneous tumors in 
immunocompromised mice. This is a surprising result, considering that in most reported 
cases with similar experimental settings, the deletion of a single gene rarely renders a 
tumorigenic phenotype in immortalized MEF. However, it is also important to point out that 
primary Ate1 KO cells, unlike the immortalized cultures, do not exhibit abnormal growth, 
suggesting that Ate1 knockout likely represents a key step in carcinogenesis rather than 
driving the whole process all by itself.
In our phenotype rescue experiments, individual recombinant Ate1 isoforms could not 
completely suppress the growth of immortalized Ate1 KO cells back to a level similar to the 
WT cells. Plausible causes may include the fact that Ate1 in these cells is represented by 
multiple isoforms and the presence of all these isoforms may be required to achieve a 
complete or near-complete rescue effect. It is also possible that the genetic plasticity seen in 
Ate1 KO cells may cause additional carcinogenic changes that cannot be rescued by the 
reintroduction of Ate1 alone. These possibilities may need to be further explored in future 
studies. At the same time, the fact that specific Ate1 isoforms can partially rescue the 
abnormal growth in these cells suggests that even in the advanced carcinogenic states Ate1 
activity continues to play a role in rendering these cells’ malignant properties. Another 
intriguing observation is the difference between the four Ate1 isoforms, which are highly 
similar in molecular weight and sequences with only small differences in their N-termini and 
the central region. These isoforms are formed by alternative splicing of highly homologous 
exons. Despite their similarity, mounting evidence already indicates their difference in 
enzymatic activity and substrate preferences (11, 13–15). While in our phenotype rescue 
experiments only Ate1-1 and Ate1-3, which share a centrally located alternatively spliced 
exon, produce an effect, it is possible that the Ate1-2 and 1–4 isoforms may participate in 
other aspects of tumorigenesis not addressed in our study.
The molecular mechanism underlying the role of Ate1 in cancer development is likely very 
complex. Ate1 is evolutionarily conserved in eukaryotes and even in some bacteria. 
Hundreds of arginylation substrates have been identified and the list is constantly expanding. 
Known substrates include cytoskeletal, chromosomal, and signaling proteins, transcription 
and translation factors, metabolic enzymes, and molecular chaperones, many of which have 
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the potential to directly and/or indirectly impact cancer-relevant processes. For example, 
published reports already found that down-regulation of Ate1 affects cell motility (4), and 
compromise cell adhesions (9) and targets proteins involved in mitosis, chromatin structure, 
apoptosis, and cell cycle (8, 16, 17), all of which are expected to contribute to carcinogenesis 
and/or metastasis (Fig. 8). Additional pathways may exist, since the current list of identified 
arginylation targets is far from complete. For example, down-regulation of Ate1 was recently 
found to transcriptionally induce loss of E-cadherin, a process that is also involved in 
epithelial-mesenchymal transition (12). The molecular mechanisms underlying the 
functional role of Ate1/arginylation in cancer development will remain an exciting and 
challenging topic for the field.
By immunohistochemistry analysis of human cancer samples and data-mining of existing 
transcription databases, our study have revealed evidence linking Ate1 to cancer 
development. Specifically, in all types of cancers that we tested, we found that down-
regulation of Ate1 contributes to tumorigenesis, metastasis, and/or patient survival. This 
evidence is consistent with the data we obtained from cell-based and animal-based tests, 
further demonstrating the robustness of our conclusions. Considering that Ate1 is an 
evolutionary conserved enzyme that is ubiquitously expressed in all tissues in the human 
body, it is likely the mechanism revealed in our study applies to many other types of cancers, 
which awaits additional work. From the clinical standpoint, the level of Ate1 has a good 
chance to be used as a predictive marker for cancer progression. While Ate1 itself may not 
be a good direct target for cancer therapy because it appears to be generally down-regulated 
in cancer, as a protein-modifying enzyme it affects many important signaling and structural 
proteins such as actin, talin, RGS, and BRCA. Lack of arginylation of those proteins may 
contribute to tumorigenesis or metastasis, and may be able to serve as direct drug targets. All 
these possibilities will need to be elucidated by future studies.
Experimental Procedures
Cell culture
Wild type and Ate1 knockout MEFs were derived from littermate E12.5 mouse embryos 
obtained from matings of Ate1 +/− mice (3). For primary cell culture experiments, MEFs 
were used for the experiments at 3rd passage after derivation. For experiments with 
immortalized cells, primary WT and Ate1 KO MEFs were immortalized by continuous 
passaging in culture as described elsewhere (3). Several independently derived primary and 
immortalized cultures were used throughout the studies to confirm consistency. MEFs were 
cultured in equal mix of DMEM (high glucose with Glutamax, Life Technologies) and F10 
(Life Technologies), supplemented with antibiotics and 10% FBS (Sigma Cat# F6178) 
unless otherwise mentioned. Cells were maintained in 5%CO2 at 37°C.
Cell multiplication studies
Cells at the beginning of the experiment were seeded at equal densities from the same 
culture into wells of 24-well plates and cell numbers per well were quantified daily by 
trypsinizing the entire well and counting using a hemocytometer.
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Cloning of pBabe-puro vector carrying Ate1-GFP
To construct mammalian expression vectors, the four isoforms (1,2,3,4) of Ate1 were 
subcloned from the template of plasmid vectors containing coding sequences for mouse 
Ate1, isoform 1, 2, 3, 4, originally constructed for bacterial expression as described in 
previous publication (18). The coding sequence of Ate1 was first cloned into a mammalian 
transient expression vector pEGFP-N2 with a forward primer: ATC AAC TCG AGA ATA 
ATT TTG TTT AAC TTT AAG AAG GAG ATA TAC ATA TG; and a reverse primer: TAC 
ATA GGA TCC CAC CGG TTC CCT GAA AAT ACA GGT TTT C, with XhoI and BamHI 
for restriction site. As a result, there is a TEV recognition sequence ENLYFQGTG and 
another linker sequence GIHRPVAT between Ate1 and eGFP. To construct a stably 
mammalian expression vector with low expression promoter, the above mentioned Ate1-
eGFP sequences were further subcloned by using a forward primer ATC TAT GAT CAG 
CCG CCA CCA TGG CTT CTT GGA GCG CGC CTT CA for Ate1-isoform 1 and 2, and 
another forward primer ATC TAT GAT CAG CCG CCA CCA TGG CCT CGG TGG TGG 
AAT ACA AG for Ate1 isoform 3 and 4, and a common reverse primer TTA ATG TCG 
ACG GCG CGC CTT ACT TGT ACA GCT CGT CCA TGC CGA GAG for eGFP. For a 
negative control, the eGFP coding sequence was subcloned with a forward primer TTA ATT 
GAT CAA CGC GTG GGC CCG GGA TCC ACC GGC CGG TCG CC and a reverse 
primer TTA ATG TCG ACG GCG CGC CTT ACT TGT ACA GCT CGT CCA TGC CGA 
GAG. The above-mentioned PCR products were cleaved with restriction enzymes Bcll and 
SalI and ligated into pBabe-Puro vector (from Cell Biolabs, INC) that was digested with 
BamHI and SalI.
Creation of stably transfected MEF
To construct retrovirus as a transfection reagent, HEK 293T cells were co-transfected with 
GAG-Pol (from Clontech), VSVG (from Clontech), and the pBabe-Puro vectors carrying 
desired Ate1-GFP coding sequence with the Lipofectamine reagent (Invitrogen). To 
construct cells stably expressing Ate1-GFP or GFP, immortalized MEF (WT and Ate1-KO) 
were transfected with retrovirus in the presence of polybrene (from Sigma). The transfected 
cells were then grown for at least five passages before being enriched by fluorescent sorting 
for the GFP signal.
Western Blot (WB)
Proteins or cell extracts were first separated on SDS-PAGE before being transferred to a 
nitrocellulose or PVDF membrane, similarly as described in (9). Protein bands were probed 
with primary antibody for either Ate1 (Millipore, cat#MABS436, clone 6F11), actin (Sigma, 
cat#A2066), beta-tubulin (Sigma, Catalog # T4026), or GFP (Roche, cat# 11814460001). 
HRP-conjugated secondary antibodies (anti-rat, Santa Cruz, cat# sc-2032; anti-rabbit/mouse, 
Roche, cat# 11520709001) and chemifluorescence reagents (from Roche cat# 11520709001) 
were used to visualize protein signal.
Matrigel assay
Matrigel (from Becton-Dickinson) was diluted by cultured medium (with 10% FBS) to 
1mg/ml and equilibrated to ~42 °C, then gently mixed with trypsinized cells to achieve even 
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distribution of cells within the media and placed into 24-well culture plate (from Corning 
Costar) to solidify. Growing colonies were observed and photographed weekly for the 
analysis shown in Fig. 4.
Analysis of Cell Cycle
For the microscopy method, WT and Ate1-KO MEF cells were seeded at 10% (for 
nonconfluent culture) or 90% (for confluent culture) and grown for 18 hours. Cells were 
incubated with 20μM EdU (Click-iT EdU Alexa Fluor-594 Imaging Kit, from ThermoFisher 
Scientific, catalogue number C10339) for one hour at 37°C in the 5% CO2 incubator. Cells 
were then fixed with 3.7% formaldehyde and permeabilized with 0.5% Triton X-100. To 
label EdU incorporated in DNA, permeabilized cells were treated with fluorescent labeling 
reaction cocktail supplied in the Click-iT EdU Imaging Kit. Hoechst 33342, also supplied 
with the kit, was used for DNA staining for identification of cells in G0/G1, G2/M phase 
based on the intensity, morphology, and distribution of nuclear DNA.
For the FACS sorting method, cells with culture densities as described above were recovered 
using trypsin, fixed with 3.7% formaldehyde, and then permeabilized with 0.1% saponine 
for fluorescent labeling with components from the Click-iT EdU Imaging Kit. After that. 4′,
6-diamidino-2-phenylindole (DAPI) was used for DNA staining.
Immunohistochemistry of tumor arrays
Kidney and colon carcinoma arrays, containing 40 pairs of matched tissue samples were 
obtained from US Biomax, Inc. To determine Ate1 levels, tissue sections in the entire array 
were stained with rat monoclonal anti-Ate1 (clone 6F11, (19)) and after image acquisiotion 
Ate1 fluorescence was quantified as gray levels using Metamorph imaging software 
(Molecular Devices). For each data point, total fluorescence in each field of view was 
normalized to DAPI staining in the same field and fluorescence from 3 fields of view was 
averaged to obtain the Ate1 levels for each tissue sample.
Immunocytochemistry
Immunocytochemistry was performed as described elsewhere (9). MEF cultured on glass 
coverslips were fixed and permeabilized by methanol and acetone. After rehydration with 
dPBS, the cells were stained with polyclonal rabbit pan-cadherin antibodies (Sigma, Cat# 
C3678) to detect adherens junctions.
Xenograft studies
4 week old mice NCRNU-M-M, homozygous, CrTac: NCr-Foxn1nu were purchased from 
Taconic. Each mouse was injected with 2 million freshly grown, gently collected cells 
suspended in 0.5 ml sterile warm PBS on each side as described in the figures and text. 
Tumor growth was observed over the course of 5–7 weeks, until the tumors became so big 
that the mice had to be euthanized. Tumor size was measured weekly using a calipher.
Analysis of Ate1 expression in human cancer arrays
ATE1 expression in normal, benign, and malignant tissues of different tumor types was 
obtained from microarray data deposited in GEO database. P values (student’s t test) are 
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indicated for significant differences between the groups. In the clinical survival analysis all 
available samples (n=739) were used to maximize statistical power.
Code availability
Computer codes for the analysis of microarray data from kidney cancer shown in the paper 
is publicly available and can be downloaded from the web address: http://
code.vet.upenn.edu/download/Ate1Cancer/. For colon cancer survival plots, we used the R 
script available in the supplemental material in (20).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ate1 knockout cells exhibit density-and serum-independent growth and early onset of 
chromosomal aberrations
A. Growth curves of immortalized WT and Ate1 KO MEF in normal culture media 
containing 10% serum (n=4). B. Growth curves of immortalized WT and Ate1 KO MEF 
grown in low serum conditions (0.5% serum). A representative curve from duplicate 
experiments is shown (see also Fig S1 for a repeat experiment using independently derived 
immortalized WT and Ate1 KO. C. Growth curves of primary WT and Ate1 KO MEF in 
normal culture media containing 10% serum (n=4). D. Karyotypes of primary wild type 
(WT) and Ate1 KO mouse embryonic fibroblasts freshly derived from E12.5 littermate 
embryos. Numbers on the y axis represent percentages of cells with each chromosome 
number shown on the x axis. Karyotypes in 20 WT cells and 27 KO cells were counted. In A 
and C, Error bars in all panels represent standard error of mean (SEM). In A, p value was 
calculated by Student’s t-test using data at the final time point (day 8).
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Figure 2. Ate1-KO cells grow differently than WT cells in dense cultures
A. Growth curves of WT and Ate1-KO MEF in low-density cultures (starting with ~30 
cells/cm2). B. Growth curve of WT and Ate1-KO MEF in high-density cultures (starting 
with ~14,000 cells/cm2). In both panels, dashed line indicates the point of 50% confluency, 
when cells would cover an estimated half of the area of the culture plates. In both panels, 
error bars represent SEM, n=6 and 5 in A and B, respectively. In B, p value was calculated 
by Student’s t-test of data at the final time point (day 4). C. Representative phase contrast 
images of overconfluent cultures of WT and Ate1-KO MEFs. While WT cells remain a 
monolayer, Ate1-KO cells tend to cluster and form foci. D. Representative fluorescence 
images of high density cultures of WT and ATE1-KO MEF stained with a pan-cadherin 
antibody that reacts with most common cadherin isoforms including N-cadherin (see also 
(9)).
Rai et al. Page 13
Oncogene. Author manuscript; available in PMC 2016 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Ate1-KO MEF have higher numbers of actively proliferating cells in near-confluent 
cultures
A. Representative images of WT and Ate1-KO MEF in scarce (<20% confluency) and 
confluent (>90% confluency) cultures. All cells were incubated for one hour with EdU, 
which was then label with Alexa 594 (red) to indicate actively proliferating cells. Cell nuclei 
were stained with Hoechst 33342 (blue). B. Quantification of cell cycle stages identified by 
EdU and Hoechst 33342 staining in randomly taken fields of view at 20x magnification in 
different culture conditions as indicated (n=5 for near-confluent WT and ATE1-KO cells, 
n=10 for scarce ATE1-KO, and n=8 for scarce WT). Error bars represent SEM. The p value 
was calculated by Student’s t-test.
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Figure 4. Ate1-KO MEF grow large colonies in Matrigel
A: Representative phase contrast images showing the morphology of the WT (left panel) and 
Ate1-KO cells (right panel) grown in Matrigel over the course of 4 weeks. B: Quantification 
of the colony outreach area (as shown in the diagram on the left) of the WT and KO Matrigel 
colonies. Error bars represent SEM. The p value was calculated by Student’s t-test.
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Figure 5. Ate1-KO MEF are capable of forming tumors in xenograft studies
Top: Photographs of mice 6 weeks after the injection of 2 million of immortalized WT and 
Ate1-KO MEFs on the left (WT) and right (KO) flanks. The injection sites are indicated 
with the asterisks. Each mouse formed visible solid tumor on the right side and showed no 
detectable growth on the left. Bottom: quantification of tumor size each week post-injection. 
n=5.
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Figure 6. Reintroduction of recombinant Ate1 partially rescues the abnormal growth and 
tumorigenicity of Ate1-KO cells
A. Left: growth curves of Ate1-KO cells stably expressing GFP (control) or recombinant 
GFP-fused Ate1-isoform 1 or −3; right: growth curves of Ate1-KO cells stably expressing 
GFP (control) or recombinant GFP-fused Ate1-isoform 2 or 4 (n=6 for all groups of cells). 
See also in Fig. S3 for the levels of exogenously expressed recombinant Ate1 in KO cells 
comparison to the endogenous Ate1 in WT cells. B. Left: representative images showing the 
subcutaneous tumors formed after injection of 2 million Ate1-KO cells stably expressing 
either Ate1-GFP (left side) or GFP (right side) after 5 weeks. Tumors are outlined on each 
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side for easier visualization. Right: quantification of the tumor growth over time. Data for 
Ate1-1 (top; n=3) and Ate1-3 (bottom; n=6) are shown (see Fig. S4 for data on Ate1-2). In 
all panels, error bars represent SEM. The p values were calculated by one-way Multivariate 
Analysis of Variance (MANOVA).
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Figure 7. Ate1 level is reduced in human cancer and inversely correlates with metastatic 
progression and survival
A. Representative images (left) and quantifications (right) of Ate1 protein levels in tissue 
arrays of human kidney and colon cancer. Matched normal and malignant tissues from the 
same patient were quantified in triplicates and averaged over the entire array. Error bars 
represent SEM, n=40 (colon) and 39 (kidney). B. The mRNA levels of Ate1 in different 
types of human kidney tumors calculated from the series matrix of GSE11151. Error bar 
represents SEM. The p-value was determined by one-tailed Welch’s t-test, denoted in the 
figures as: *** for p<0.001, ** for p<0.01, and * for p<0.05. C. Kaplan–Meier survival plots 
in colon cancer patients with high and low levels of Ate1 mRNA of were generated utilizing 
a previously established database (21). The following datasets were used: GSE12945 
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GSE14333 GSE17538 GSE31595 GSE33114 GSE37892 GSE38832 GSE39582 and 
GSE41258. Cox proportional hazards regression analysis was performed as described in 
(20). D. The mRNA level of Ate1 in normal, benign, and malignant prostate tissues obtained 
from microarray data deposited in GEO database. P values (student’s t test) are indicated for 
significant differences between the groups (N.S., non-significant (P>0.1)).
Rai et al. Page 20
Oncogene. Author manuscript; available in PMC 2016 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 8. Down-regulation of Ate1 can affect tumorigenesis and metastasis
through multiple pathways involving known arginylation protein targets with functions in 
apoptosis, mitosis, chromatin structure, cell motility and adhesions.
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